secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001558370-24-006202
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS publishes study showing PMN310's superior oligomer selectivity vs other Aβ antibodies
--------------------------------------------------------------------------------

- PMN310 displayed greatest selectivity for toxic soluble Aβ oligomers among tested antibodies.
- PMN310 avoided binding to plaque and vascular deposits, potentially reducing ARIA-E and ARIA-H risks.
- Weekly murine PMN310 dosing at 800 mg/kg for 26 weeks in AD mice showed no detectable brain hemorrhages.
- Phase 1a study in healthy volunteers ongoing; initial safety/PK data expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/0001558370-24-006202-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837024006202/pmn-20240430x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006202

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer